Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score.

Pharmacogenomics - 1 Nov 2020

Gilani Syed Sa, Nair Nisha, Plant Darren, Hyrich Kimme, Morgan Ann W, Morris Andrew P, Wilson Anthony G, Isaacs John D, Barton Anne, Bluett James

Abstract excerpt

Aim: TNF inhibitor drugs are a treatment option for rheumatoid arthritis, but response is not universal. Response is typically measured using the composite 4-component (4C) disease activity score 28 (DAS28) which contains more subjective measures. This study used a validated 2-component (2C) DAS28 score to determine whether SNPs associated with response were replicated in the UK population. Materials & methods: A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arthritis, Rheumatoid
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Severity of Illness Index

Share to Treatment Failure

Share to Treatment Outcome

Share to Tumor Necrosis Factor-alpha

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 33124499
DOI: 10.2217/pgs-2020-0043
PMCID: PMC7649675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score.PMID 33124499Read ↗

Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy.Semantic proximity Read ↗

Genetic and Genomic Markers of Anti-TNF Treatment Response in Rheumatoid ArthritisSemantic proximity Read ↗

Genetic and genomic predictors of anti-TNF response.Semantic proximity Read ↗

Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.Semantic proximity Read ↗

Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.Semantic proximity Read ↗

Integration of Known DNA, RNA and Protein Biomarkers Provides Prediction of Anti-TNF Response in Rheumatoid Arthritis: Results from the COMBINE StudySemantic proximity Read ↗

Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis.Semantic proximity Read ↗

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?Semantic proximity Read ↗

Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directionsSemantic proximity Read ↗

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?Semantic proximity Read ↗

Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.